• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Emergency

Dexamethasone vs placebo for acute sore throat in adults

byMichael MilliganandSusy Lam
April 20, 2017
in Emergency, Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. This double-blinded, placebo-control trial found that, among patients with acute sore throat, those who received dexamethasone were no more likely than those who received placebo to have complete symptom resolution at 24 hours.

2. At 48 hours, more participants receiving dexamethasone had symptom resolution compared to those who received placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Acute sore throat is a common presenting symptom for patients seeking urgent care. Antibiotics are prescribed during a majority of visits (60% of primary care consultations in UK), despite limited symptomatic benefit and national guidelines advising against their use. Corticosteroids have been shown to be effective in upper respiratory tract infections such as acute sinusitis and croup. However, the effectiveness of corticosteroids without antibiotics for sore throat in primary care has not yet been established. This double-blinded, randomized, placebo-controlled study found patients who received dexamethasone were not more likely than placebo to have complete symptom resolution at 24 hours. However, at 48 hours, more patients who received dexamethasone had complete symptom resolution compared to placebo.

This study was the first to describe effect of oral corticosteroids for acute sore throat in a primary care setting. Some limitations include selection bias, as the study recruited patients with milder symptoms of sore throat and excluded those deemed to require immediate antibiotics. Children were likewise excluded. Furthermore, this study was underpowered, and a larger study needs to be done to validate a statistically significant difference between treatments in acute sore throat symptom resolution. Overall, this study provides data that dexamethasone does not significantly improve acute sore throat symptoms compared to placebo, 24 hours post-presentation.

Click to read the study, published in JAMA

Relevant Reading: Prescribing of Antibiotics for Self-Limiting Respiratory Tract Infections in Adults and Children in Primary Care

RELATED REPORTS

Molnupiravir does not reduce COVID-19-related hospitalizations in vaccinated adults

Routine dexamethasone is not effective compared to placebo to treat dyspnea in patients with advanced cancer

The RECOVERY trial: Dexamethasone decreased mortality in hospitalized COVID-19 patients [Classics Series]

In-Depth [randomized control study]: This multi-centered, randomized, double-blinded, placebo-controlled study took place across 42 general practice clinics in England between 2013-2015. Patients with acute sore throat were followed up for 28 days after randomization into either an intervention group of dexamethasone tablets (n = 293) or a control group with a placebo capsule (n = 283). The primary outcome was complete resolution of sore throat symptoms at 24 hours, reported by the patient through phone or text message. Secondary outcomes were complete resolution at 48 hours and the total duration of moderately severe symptoms as recorded in a validated 7-day symptom diary. After following up with patients at 24 hours, it was found that a single dose of oral dexamethasone did not significantly decrease the number of patients with complete sore throat resolution (22.6% of dexamethasone group, vs. 17.7% of placebo group; RR 1.28 [95% CI, 0.92-1.78, p = 0.14]). By 48 hours, 35.4% of patients in the dexamethasone group vs. 27.1% in the placebo group experienced complete resolution of symptoms (RR 131 [95% CI, 1.2%-16.2%]). Dexamethasone did not result in a significant difference in mean number of hours missed from work or education (mean difference 0.24 hours longer in dexamethasone group; 95%CI −2.14 to 2.61; p = 0.85), nor were there significant differences in the number of participants who required medical care at the emergency department, urgent care, or their GP clinic.

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: dexamethasonesore throat
Previous Post

Targeted HIV-screening practices more effective for minority youths

Next Post

Risankizumab more effective than ustekinumab for moderate-to-severe psoriasis

RelatedReports

Novel coronavirus identified from patients with pneumonia in Wuhan, China
Infectious Disease

Molnupiravir does not reduce COVID-19-related hospitalizations in vaccinated adults

February 7, 2023
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial

Routine dexamethasone is not effective compared to placebo to treat dyspnea in patients with advanced cancer

September 12, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
COVID-19 Classics

The RECOVERY trial: Dexamethasone decreased mortality in hospitalized COVID-19 patients [Classics Series]

July 16, 2022
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

High dose dexamethasone does not improve survival in patients with hypoxemic respiratory failure due to COVID-19

July 7, 2022
Next Post
Patients with psoriasis associated with increased systemic arterial and subcutaneous adipose inflammation

Risankizumab more effective than ustekinumab for moderate-to-severe psoriasis

Long-term outcomes for off-pump and on-pump CABG are similar

Mixed cardiovascular benefit with PCSK9 inhibitior bococizumab: The SPIRE trial

Adalimumab aids in control of noninfectious uveitis

Individualized screening for diabetic retinopathy with fundoscopy and HbA1c

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Momelotinib reduces symptom burden compared to danazol in patients with myelofibrosis
  • Machine renal perfusion reduces delayed graft function after transplantation
  • COVID-19 mRNA vaccines are safe and effective in children aged 5 to 11 years
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options